1.87

1.94% -0.037

After Hours: 1.87

Lixte Biotechnology Holdings Inc (LIXT)

Overview News Price History Financials Discussions Forecast Stock Split

Lixte Biotechnology Holdings Inc stock is traded at $1.87, with a volume of 4,606. It is down -1.94% in the last 24 hours and up +5.06% over the past month. Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

Previous Close:

$1.907

Open:

$1.96

24h Volume:

4,606

Relative Volume:

0.09

Market Cap:

$4.21M

Revenue:

Net Income/Loss:

$-4.69M

P/E Ratio:

-0.5054

EPS:

-3.7

Net Cash Flow:

$-3.81M

1W Performance:

+1.63%

1M Performance:

+5.06%

6M Performance:

-44.67%

1Y Performance:

-23.67%

1-Day Range:

$1.86

$1.96

1-Week Range:

$1.79

$1.98

52-Week Range:

$1.55

$4.42

Lixte Biotechnology Holdings Inc Stock (LIXT) Company Profile

Name

Lixte Biotechnology Holdings Inc

Sector

Healthcare (1190)

Industry

Biotechnology (681)

Phone

310 203 2902

Address

248 ROUTE 25A, EAST SETAUKET

Employee

Twitter

Next Earnings Date

2024-08-08

Latest SEC Filings

LIXT's Discussions on Twitter

Lixte Biotechnology Holdings Inc Stock (LIXT) Latest News

Sep 24, 2024

Lixte Biotechnology (NASDAQ:LIXT) Stock Price Down 2.1% - Defense World

Sep 24, 2024

LIfT BioSciences raises £10m in first close of Series A to advance first-in-class allogeneic innate cell therapy - GlobeNewswire

Sep 24, 2024

Sep 23, 2024

Should investors be concerned about LYT’s high price-to-sales ratio? - US Post News

Sep 23, 2024

Lilium (NASDAQ:LILM) Earns Overweight Rating from Cantor Fitzgerald - MarketBeat

Sep 23, 2024

Liquidia Co. (NASDAQ:LQDA) Shares Bought by Rhumbline Advisers - Defense World

Sep 23, 2024

Pacer Advisors Inc. Has $16.07 Million Stock Position in Liquidity Services, Inc. (NASDAQ:LQDT) - Defense World

Sep 23, 2024

Lipella Pharmaceuticals Inc’s Market Journey: Closing Weak at 0.41, Down -2.35 - The Dwinnex

Sep 23, 2024

Renaissance Technologies LLC Sells 2,000 Shares of LSI Industries Inc. (NASDAQ:LYTS) - Defense World

Sep 23, 2024

Sep 22, 2024

Texas Permanent School Fund Corp Trims Position in Liquidity Services, Inc. (NASDAQ:LQDT) - Defense World

Sep 22, 2024

Sep 21, 2024

First Eagle Investment Management LLC Increases Stake in LSI Industries Inc. (NASDAQ:LYTS) - Defense World

Sep 21, 2024

Huber Capital Management LLC Acquires 241,814 Shares of Lyft, Inc. (NASDAQ:LYFT) - Defense World

Sep 21, 2024

Acadian Asset Management LLC Cuts Position in LSI Industries Inc. (NASDAQ:LYTS) - Defense World

Sep 21, 2024

Quest Partners LLC Invests $28,000 in LSI Industries Inc. (NASDAQ:LYTS) - Defense World

Sep 21, 2024

Sep 19, 2024

Investors who lost money with shares of Liquidia Corporation - openPR

Sep 19, 2024

Sep 18, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia CorporationLQDA - Kilgore News Herald

Sep 18, 2024

Sep 10, 2024

Biotech Steals The Show Following Pre-Clinical Data Announcement - MSN

Sep 10, 2024

Sep 05, 2024